BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > Note this part of the nr

<< Previous

Bullboard Posts

Next >>

Comment by Humaniston Jun 03, 2022 1:38pm

79 Views

Post# 34730160

RE:Note this part of the nr

excellent highlight frankman, the fact they invited tem again to get an update shows strong interest and faith in their reserach. and for us investors, means biovayxys has agreat potential of reaching their end goal..
glta

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec